Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B R De Young

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Cancer|October 28, 1999
MOC-31 aids in the differentiation of metastatic adenocarcinoma from hepatocellular carcinomaT H Niemann, J H Hughes, B R De Young
American Journal of Clinical Pathology|August 15, 1998
Biopsy bag artifactT H Niemann, J G Tranovich, B R De Young
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 1, 1997
Anti-MOC-31: a potential addition to the pulmonary adenocarcinoma versus mesothelioma immunohistochemistry panelR C Sosolik, V R McGaughy, B R De Young
Human Pathology|March 24, 1999
Altered expression of gamma-glutamyl transpeptidase in human tumorsM H Hanigan, H F Frierson, P E Swanson, et al.
Cancer|December 22, 1999
MOC-31 aids in the differentiation between adenocarcinoma and reactive mesothelial cellsR L Morgan, B R De Young, V R McGaughy, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 27, 2000
Immunohistochemical analysis of hepatocellular and adenocarcinoma in the liver: MOC31 compares favorably with other putative markersA I Porcell, B R De Young, D M Proca, et al.
International Journal of Oncology|December 24, 1998
Altered localization of E-cadherin and alpha-catenin in rat esophageal tumorsL Khare, C L Sabourin, B R De Young, et al.
American Journal of Clinical Pathology|September 5, 1998
CD31 immunoreactivity in carcinomas and mesotheliomasB R De Young, H F Frierson, M N Ly, et al.
Clinical Genetics|August 7, 2009
BRCA2 alteration is important in clear cell carcinoma of the ovaryM J Goodheart, S L Rose, M Hattermann-Zogg, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Cancer|October 28, 1999
MOC-31 aids in the differentiation of metastatic adenocarcinoma from hepatocellular carcinomaT H Niemann, J H Hughes, B R De Young
American Journal of Clinical Pathology|August 15, 1998
Biopsy bag artifactT H Niemann, J G Tranovich, B R De Young
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 1, 1997
Anti-MOC-31: a potential addition to the pulmonary adenocarcinoma versus mesothelioma immunohistochemistry panelR C Sosolik, V R McGaughy, B R De Young
Human Pathology|March 24, 1999
Altered expression of gamma-glutamyl transpeptidase in human tumorsM H Hanigan, H F Frierson, P E Swanson, et al.
Cancer|December 22, 1999
MOC-31 aids in the differentiation between adenocarcinoma and reactive mesothelial cellsR L Morgan, B R De Young, V R McGaughy, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 27, 2000
Immunohistochemical analysis of hepatocellular and adenocarcinoma in the liver: MOC31 compares favorably with other putative markersA I Porcell, B R De Young, D M Proca, et al.
International Journal of Oncology|December 24, 1998
Altered localization of E-cadherin and alpha-catenin in rat esophageal tumorsL Khare, C L Sabourin, B R De Young, et al.
American Journal of Clinical Pathology|September 5, 1998
CD31 immunoreactivity in carcinomas and mesotheliomasB R De Young, H F Frierson, M N Ly, et al.
Clinical Genetics|August 7, 2009
BRCA2 alteration is important in clear cell carcinoma of the ovaryM J Goodheart, S L Rose, M Hattermann-Zogg, et al.
Pageof 1